216 related articles for article (PubMed ID: 11250722)
1. Future possibilities in the prevention of breast cancer: intervention strategies in BRCA1 and BRCA2 mutation carriers.
Eeles RA
Breast Cancer Res; 2000; 2(4):283-90. PubMed ID: 11250722
[TBL] [Abstract][Full Text] [Related]
2. Breast cancer genetics. Implications of clinical practice.
Olufunmilayo I; Olopade MD; Fackenthal JD
Hematol Oncol Clin North Am; 2000 Jun; 14(3):705-25. PubMed ID: 11203330
[No Abstract] [Full Text] [Related]
3. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
Eeles RA; Powles TJ
J Clin Oncol; 2000 Nov; 18(21 Suppl):93S-9S. PubMed ID: 11060334
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 mutations in central and southern Italian patients.
Ottini L; D'Amico C; Noviello C; Lauro S; Lalle M; Fornarini G; Colantuoni OA; Pizzi C; Cortesi E; Carlini S; Guadagni F; Bianco AR; Frati L; Contegiacomo A; Mariani-Costantini R
Breast Cancer Res; 2000; 2(4):307-10. PubMed ID: 11056688
[TBL] [Abstract][Full Text] [Related]
5. Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer.
Møller P; Evans G; Haites N; Vasen H; Reis MM; Anderson E; Apold J; Hodgson S; Eccles D; Olsson H; Stoppa-Lyonnet D; Chang-Claude J; Morrison PJ; Bevilacqua G; Heimdal K; Maehle L; Lalloo F; Gregory H; Preece P; Borg A; Nevin NC; Caligo M; Steel CM
Dis Markers; 1999 Oct; 15(1-3):207-11. PubMed ID: 10595280
[TBL] [Abstract][Full Text] [Related]
6. Molecular cancer genetics in eastern and central Europe.
Olah E
Dis Markers; 1999 Oct; 15(1-3):75-7. PubMed ID: 10595256
[No Abstract] [Full Text] [Related]
7. Hereditary susceptibility to breast cancer: significance of age of onset in family history and contribution of BRCA1 and BRCA2.
Frank TS; Deffenbaugh AM; Hulick M; Gumpper K
Dis Markers; 1999 Oct; 15(1-3):89-92. PubMed ID: 10595259
[TBL] [Abstract][Full Text] [Related]
8. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
Chang-Claude J; Becher H; Caligo M; Eccles D; Evans G; Haites N; Hodgson S; Møller P; Weber BH; Stoppa-Lyonnet D
Dis Markers; 1999 Oct; 15(1-3):53-65. PubMed ID: 10595253
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 mutation carriers as potential candidates for chemoprevention trials.
Levy-Lahad E; Krieger M; Gottfeld O; Renbaum P; Klein G; Eisenberg S; Lahad A; Kaufman B; Catane R
J Cell Biochem Suppl; 2000; 34():13-8. PubMed ID: 10762009
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
[TBL] [Abstract][Full Text] [Related]
11. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification of a Belgian founder mutation BRCA1 IVS5 + 3A > G.
Claes K; Machackova E; De Vos M; Poppe B; De Paepe A; Messiaen L
Dis Markers; 1999 Oct; 15(1-3):69-73. PubMed ID: 10595255
[TBL] [Abstract][Full Text] [Related]
12. Familial breast and ovarian cancer: genetic counseling and clinical management in Italy.
Pasini B; Pierotti MA
Dis Markers; 1999 Oct; 15(1-3):41-3. PubMed ID: 10595250
[No Abstract] [Full Text] [Related]
13. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
[TBL] [Abstract][Full Text] [Related]
14. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
Struewing JP; Hartge P; Wacholder S; Baker SM; Berlin M; McAdams M; Timmerman MM; Brody LC; Tucker MA
N Engl J Med; 1997 May; 336(20):1401-8. PubMed ID: 9145676
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
[TBL] [Abstract][Full Text] [Related]
16. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
[TBL] [Abstract][Full Text] [Related]
17. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing.
de la Hoya M; Osorio A; Godino J; Sulleiro S; Tosar A; Perez-Segura P; Fernandez C; Rodríguez R; Díaz-Rubio E; Benítez J; Devilee P; Caldés T
Int J Cancer; 2002 Feb; 97(4):466-71. PubMed ID: 11802208
[TBL] [Abstract][Full Text] [Related]
18. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
Lavie O; Narod S; Lejbkowicz F; Dishon S; Goldberg Y; Gemer O; Rennert G
Ann Oncol; 2011 Apr; 22(4):964-966. PubMed ID: 20924075
[TBL] [Abstract][Full Text] [Related]
19. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
Hartge P; Struewing JP; Wacholder S; Brody LC; Tucker MA
Am J Hum Genet; 1999 Apr; 64(4):963-70. PubMed ID: 10090881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]